Skip to main content

Table 1 Common clinical manifestation of NSD2 truncating mutation cases

From: The first familial NSD2 cases with a novel variant in a Chinese father and daughter with atypical WHS facial features and a 7.5-year follow-up of growth hormone therapy

Phenotype

Percentage in NSD2 patients

Percentage in WHS patients

Total number of patients

10

> 300

Intellectual disability/Developmental delay

100% (10/10)

> 75%

Ear abnormal

88% (7/8)

> 75%

Hypertelorism

86% (6/7)

> 75%

High-arched eyebrows

86% (6/7)

> 75%

Wide nasal bridge

86% (6/7)

> 75%

Abnormal teetha

86% (6/7)

50–75%

Hypotonia

80% (8/10)

> 75%

Intrauterine/postnatal growth retardation

80% (8/10)

> 75%

Feeding difficulties

78% (7/9)

> 75%

Microcephalya

60% (6/10)

> 75%

Micrognathiaa

57% (4/7)

> 75%

Epicanthal foldsa

57% (4/7)

> 75%

Downturned corners of moutha

57% (4/7)

> 75%

Skeletal anomalies

50% (3/6)

50–75%

Short philtruma

43% (3/7)

> 75%

Stereotypies (hand washing/flapping, rocking)

33% (2/6)

25–50%

Prominent glabellaa

29% (2/7)

> 75%

Craniofacial asymmetrya

29% (2/7)

50–75%

High foreheada

25% (2/8)

> 75%

Hearing loss

25% (1/4)

25–50%

Skin changes (hemangioma; marble/dry skin)a

20% (1/5)

50–75%

Genitourinary tract anomaliesa

17% (1/6)

25–50%

Gut anomalies

17% (1/6)

< 25%

Esophagus anomalies

17% (1/6)

< 25%

Structural brain anomaliesa

14% (1/7)

25–50%

Liver anomalies

14% (1/7)

< 25%

Seizures and/or distinctive Electroencephalogram abnormalitiesa

11% (1/9)

> 75%

  1. WHS Wolf-Hirschhorn syndrome, HGVS Human genome variation society, NA Not Available
  2. afeatures with different incidence rates in NSD2 and WHS patients